Compare MDA & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDA | AMRX |
|---|---|---|
| Founded | 1969 | 2002 |
| Country | Canada | United States |
| Employees | 4000 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2026 | 2018 |
| Metric | MDA | AMRX |
|---|---|---|
| Price | $32.24 | $12.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.50 | $15.60 |
| AVG Volume (30 Days) | 689.6K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $12.11 | $4.48 |
| Revenue Next Year | $11.03 | $7.13 |
| P/E Ratio | ★ N/A | $57.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.23 | $7.02 |
| 52 Week High | $37.45 | $15.42 |
| Indicator | MDA | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 45.67 |
| Support Level | $23.23 | $12.50 |
| Resistance Level | $33.75 | $12.85 |
| Average True Range (ATR) | 1.75 | 0.49 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 44.63 | 28.01 |
MDA Space Ltd is a developer and manufacturer of technology and services to the space industry. It is an international space mission partner and robotics, satellite systems, and geo-intelligence pioneer. It is engaged in communications satellites, Earth and space observation, space exploration, and infrastructure. The Company collaborates and partners with governments and space agencies, commercial space companies, and defence and aerospace prime contractors in the space industry. Geographically, it generates the majority of its revenue from Canada.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.